Paushak [PAUSHAKLTD] vs Kingfa Science [KINGFA] Detailed Stock Comparison
Paushak
BSE
Loading...
Kingfa Science
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Paushak wins in 10 metrics, Kingfa Science wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Paushak | Kingfa Science | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 36.23 | 30.12 | Kingfa Science |
| Price-to-Book Ratio | 3.98 | 6.35 | Paushak |
| Debt-to-Equity Ratio | 5.37 | 5.90 | Paushak |
| PEG Ratio | 2.16 | 16.19 | Paushak |
| EV/EBITDA | 28.26 | 20.76 | Kingfa Science |
| Profit Margin (TTM) | 23.79% | 8.58% | Paushak |
| Operating Margin (TTM) | 24.69% | 11.17% | Paushak |
| EBITDA Margin (TTM) | 24.69% | 11.17% | Paushak |
| Return on Equity | 10.61% | 20.98% | Kingfa Science |
| Return on Assets (TTM) | 8.63% | 13.23% | Kingfa Science |
| Free Cash Flow (TTM) | $-1.23B | $295.94M | Kingfa Science |
| Dividend Yield | 0.77% | 0.32% | Paushak |
| 1-Year Return | -4.20% | 23.04% | Kingfa Science |
| Price-to-Sales Ratio (TTM) | 8.63 | 2.58 | Kingfa Science |
| Enterprise Value | $18.71B | $46.42B | Kingfa Science |
| EV/Revenue Ratio | 8.71 | 2.59 | Kingfa Science |
| Gross Profit Margin (TTM) | 82.39% | 22.30% | Paushak |
| Revenue per Share (TTM) | $697 | $1,478 | Kingfa Science |
| Earnings per Share (Diluted) | $166.09 | $126.75 | Paushak |
| Beta (Stock Volatility) | -0.05 | 0.66 | Paushak |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Paushak vs Kingfa Science Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Paushak | -0.12% | -1.49% | 7.16% | 29.99% | 40.20% | 21.89% |
| Kingfa Science | 8.58% | 18.50% | 23.10% | 25.42% | 53.39% | 21.20% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Paushak | -4.20% | -36.84% | 52.32% | 566.74% | 7,055.54% | 1,875.56% |
| Kingfa Science | 23.04% | 236.78% | 744.94% | 1,437.86% | 12,024.31% | 13,791.76% |
Performance & Financial Health Analysis: Paushak vs Kingfa Science
| Metric | PAUSHAKLTD | KINGFA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹18.55B | ₹46.24B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 7,214 | 17,014 |
| 90 Day Avg. Volume | 4,539 | 14,157 |
| Last Close | ₹6,010.65 | ₹4,145.30 |
| 52 Week Range | ₹3,746.00 - ₹6,385.00 | ₹2,550.00 - ₹4,190.00 |
| % from 52W High | -5.86% | -1.07% |
| All-Time High | ₹12,400.00 (Apr 11, 2022) | ₹4,190.00 (Aug 18, 2025) |
| % from All-Time High | -51.53% | -1.07% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.11% |
| Quarterly Earnings Growth | 0.17% | 0.02% |
| Financial Health | ||
| Profit Margin (TTM) | 0.24% | 0.09% |
| Operating Margin (TTM) | 0.25% | 0.11% |
| Return on Equity (TTM) | 0.11% | 0.21% |
| Debt to Equity (MRQ) | 5.37 | 5.90 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹1,510.29 | ₹601.64 |
| Cash per Share (MRQ) | ₹27.70 | ₹19.54 |
| Operating Cash Flow (TTM) | ₹389.47M | ₹993.76M |
| Levered Free Cash Flow (TTM) | ₹493.77M | ₹1.53B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.77% | 0.32% |
| Last 12-Month Dividend | ₹40.00 | ₹10.00 |
Valuation & Enterprise Metrics Analysis: Paushak vs Kingfa Science
| Metric | PAUSHAKLTD | KINGFA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 36.23 | 30.12 |
| Forward P/E | 140.93 | N/A |
| PEG Ratio | 2.16 | 16.19 |
| Price to Sales (TTM) | 8.63 | 2.58 |
| Price to Book (MRQ) | 3.98 | 6.35 |
| Market Capitalization | ||
| Market Capitalization | ₹18.55B | ₹46.24B |
| Enterprise Value | ₹18.71B | ₹46.42B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.71 | 2.59 |
| Enterprise to EBITDA | 28.26 | 20.76 |
| Risk & Other Metrics | ||
| Beta | -0.05 | 0.66 |
| Book Value per Share (MRQ) | ₹1,510.29 | ₹601.64 |
Financial Statements Comparison: Paushak vs Kingfa Science
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PAUSHAKLTD | KINGFA |
|---|---|---|
| Revenue/Sales | ₹558.80M | ₹4.70B |
| Cost of Goods Sold | ₹98.40M | ₹3.63B |
| Gross Profit | ₹460.40M | ₹1.07B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹137.90M | ₹905.70M |
| EBITDA | ₹197.30M | ₹623.82M |
| Pre-Tax Income | ₹156.30M | ₹543.29M |
| Income Tax | ₹36.00M | ₹124.31M |
| Net Income (Profit) | ₹120.30M | ₹418.98M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PAUSHAKLTD | KINGFA |
|---|---|---|
| Cash & Equivalents | ₹142,000 | ₹234.80M |
| Total Current Assets | ₹995.83M | ₹8.54B |
| Total Current Liabilities | ₹444.39M | ₹4.22B |
| Long-Term Debt | ₹250.00M | ₹20.61M |
| Total Shareholders Equity | ₹4.65B | ₹7.29B |
| Retained Earnings | N/A | ₹4.55B |
| Property, Plant & Equipment | ₹171.74M | ₹2.44B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PAUSHAKLTD | KINGFA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PAUSHAKLTD | KINGFA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 7,214 | 17,014 |
| Average Daily Volume (90 Day) | 4,539 | 14,157 |
| Shares Outstanding | 3.08M | 12.11M |
| Float Shares | 886,385 | 1.66M |
| % Held by Insiders | 0.71% | 0.86% |
| % Held by Institutions | 0.00% | 0.00% |
Dividend Analysis & Yield Comparison: Paushak vs Kingfa Science
| Metric | PAUSHAKLTD | KINGFA |
|---|---|---|
| Last 12-Month Dividend | ₹40.00 | ₹10.00 |
| Last 12-Month Dividend Yield | 0.77% | 0.32% |
| 3-Year Avg Annual Dividend | ₹23.17 | ₹3.33 |
| 3-Year Avg Dividend Yield | 0.27% | 0.30% |
| 3-Year Total Dividends | ₹69.50 | ₹10.00 |
| Ex-Dividend Date | Jul 24, 2025 | Sep 17, 2024 |